Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) plummeted 5.78% in after-hours trading on Monday, October 29, 2024, following the company's third-quarter 2024 financial results and pipeline updates.
The biopharmaceutical company reported a narrower net loss of $93.6 million for the quarter, compared to a net loss of $201.6 million in the same period last year. However, the market reacted negatively to Sage's decision to halt further development of its investigational drug zuranolone as a treatment for major depressive disorder (MDD) in the U.S.
Sage and its partner Biogen had previously received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for zuranolone in MDD. The companies concluded that the significant additional investment and time required for further studies made the MDD program commercially unviable in the U.S. market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。